Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12
This article reports a significant 14.60% decrease in the price target for Janux Therapeutics (JANX), bringing it down to $42.12. The specific reasons or analyst behind this adjustment are not detailed in the provided content.
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12
This article reports a significant decrease in the price target for Janux Therapeutics (JANX) by 14.60%, bringing it down to $42.12. This adjustment suggests a revised outlook from analysts regarding the company's future stock performance and valuation. The specific reasons for this reduction were not detailed in the provided content.
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX)
Maria Dobek, Vice President of Accounting at Janux Therapeutics Inc (JANX), sold 2,038 shares of the company on May 11, 2026, and now holds 32,270 shares. This transaction is part of a pattern of 10 insider sells and no buys over the past year. The stock is currently trading at $14.17, with a GF Value of $34.56, suggesting it might be a "Possible Value Trap, Think Twice."
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17
Maria Dobek, Vice President of Accounting at Janux Therapeutics (JANX), sold 2,038 shares of company common stock in an open-market transaction on May 11, 2026, at a price of $14.17 per share. This sale reduced her direct holdings to 32,270 shares. The transaction, valued at approximately $29,000, was reported in an SEC Form 4 filing.
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts
Analysts have significantly upgraded their forecasts for Janux Therapeutics, Inc. (NASDAQ:JANX), increasing revenue estimates for 2026 to US$34 million and reducing projected losses per share to US$1.77. This suggests a notable improvement in business fundamentals and an expectation of accelerated growth. Despite the positive outlook on revenues and reduced losses, the consensus price target coincidentally fell by 8.1% to US$40.56, indicating some continued pessimism among analysts.
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44%
This article discusses the potential upside for Janux Therapeutics (JANX) as perceived by Wall Street analysts, who estimate a significant increase of 180.44%. It suggests that the stock could see substantial growth based on current analyst projections.
Janux Therapeutics halts early stage cancer program in 'prudent' move
Janux Therapeutics has announced the discontinuation of its early-stage cancer drug program, JANX008, affecting non-small cell lung cancer patients. The decision was made following an internal strategic review, which determined that while the drug showed anti-tumor activity and was well-tolerated, its potential for differentiation in the competitive treatment landscape was insufficient. The company will now reallocate resources to its other clinical programs, including JANX007 and JANX003, which target different cancer types.
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics
State Street Corporation has reported a beneficial ownership of 4.1% in Janux Therapeutics common stock, amounting to 2,464,017 shares as of March 31, 2026. This disclosure, made via a SCHEDULE 13G filing, indicates shared voting power over 2,373,058 shares and shared dispositive power over 2,464,017 shares, signifying a passive institutional holding rather than an intent to control. The filing identifies several affiliated advisory entities of State Street as the holders of these shares.
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright has reiterated its Buy rating for Janux Therapeutics (JANX.US), maintaining a target price of $45. This re-affirmation indicates the firm's continued confidence in the company's financial prospects and stock performance.
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Janux Therapeutics (NASDAQ:JANX) recently reported its quarterly results, showing mixed performance with lower-than-predicted revenues but smaller losses. Analysts have since upgraded revenue estimates for 2026 to US$34.5m and reduced loss estimates to US$1.72 per share, indicating a shift in sentiment despite a drop in the consensus price target to US$40.56. The company is expected to see significant growth, projected at 241% annualized to 2026, outperforming the industry average.
Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Janux Therapeutics (NASDAQ: JANX) recently reported quarterly results, which showed mixed outcomes with revenues 20% lower than predicted but losses 25% smaller. Analysts have since upgraded their revenue estimates for 2026 to US$34.5 million and reduced loss estimates to US$1.72 per share, indicating a change in sentiment. Despite the improved revenue and earnings outlook, the consensus price target fell by 8.1% to US$40.56, reflecting continued pessimism among analysts and a wide range of future valuation estimates.
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
H.C. Wainwright analyst Swayampakula Ramakanth has reiterated a Buy rating on Janux Therapeutics (JANX) with an unchanged $45 price target. This positive outlook is primarily driven by the advancement of Janux's PSMA-focused oncology pipeline, including ongoing clinical trials for JANX007 and JANX014, and the planned clinical entry of JANX013. Additionally, the company's strong cash position of $956 million, expected to support operations well into the future, contributes to the sustained Buy rating despite the discontinuation of an earlier program.
Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives
Janux Therapeutics (JANX) reported Q4 FY 2025 revenue of US$0 and a trailing twelve-month net loss of US$113.6 million, an increase from US$60.5 million the prior year. Despite analysts forecasting 53.48% annual revenue growth, earnings are expected to decline by 15.3% per year, and the company has been unprofitable for five years. The article discusses how widening losses and persistent unprofitability reinforce bearish views, even as the stock trades at a low price-to-book ratio compared to industry averages.
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
Bank of America Securities reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $21.00. This follows Janux Therapeutics reporting a quarterly revenue of $7.88 million and a GAAP net loss of $31.95 million for the quarter ending December 31. Another analyst from TD Cowen also issued a Buy rating, while Barclays assigned a Sell rating on the same day.
Janux Therapeutics (JANX) Eps Diluted (TTM)
This article from Zacks.com provides financial data and analyst insights for Janux Therapeutics (JANX), focusing on its Diluted EPS (TTM). It details stock performance, Zacks Rank, Style Scores, Industry Rank, and recent news including Q1 earnings loss, analyst price target adjustments, and ongoing pipeline advancements.
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
Bank of America Securities reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a $21.00 price target. This comes despite Barclays assigning a Sell rating on the same day. Janux Therapeutics reported a quarterly revenue of $7.88 million and a GAAP net loss of $31.95 million for the quarter ending December 31.
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.94, Implies 182% Upside
Janux Therapeutics, Inc.'s average 12-month stock price target has been reduced from $44.18 to $40.41 by 17 analysts, ranging from $14 to $95 per share. Despite this cut, the updated target implies a significant 178% potential upside based on the May 7 closing price. The consensus rating from 19 analysts remains "Buy," with 15 Buys, 3 Holds, and 1 Sell recommendation.
RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating
RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) shares to $30 from $27, while maintaining an "Outperform" rating on the stock. This adjustment comes despite the company recently discontinuing the clinical development of one of its cancer drug candidates, JANX008, as announced by MT Newswires.
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $40.41, Implies 178% Upside
Janux Therapeutics, Inc.'s stock has seen its average 12-month price target cut from $44.18 to $40.41 by 17 analysts, with a range spanning $14 to $95 per share. Despite the cut, the new target still implies a significant potential upside of approximately 178% based on the May 7 closing price. The consensus rating from 19 analysts remains a "Buy," with 15 recommending Buy, 3 Hold, and 1 Sell.
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its Q1 2026 financial results, highlighting ongoing clinical progress for its prostate cancer drug candidates JANX007 and JANX014, and advancing JANX013 towards the clinic. The company also announced the discontinuation of JANX008 to reallocate resources and provided financial figures including $956.4 million in cash and short-term investments, and a net loss of $24.4 million for the quarter. Future milestones include additional clinical data for JANX007 in early 2027 and an initial clinical update for JANX011 in late 2026.
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
JonesTrading analyst Boris Peaker has reiterated a Buy rating on Janux Therapeutics (JANX) due to its promising clinical pipeline and undervalued stock. Peaker highlights upcoming Phase I readouts and planned clinical developments for several drug candidates, noting the stock trades at near-zero or negative enterprise value. He believes positive safety data and durable responses could significantly re-rate the stock, offering an appealing risk/reward profile given its strong cash position.
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for the first quarter of 2026, highlighting continued progress in its prostate cancer and autoimmune disease franchises. Key developments include ongoing enrollment for JANX007 in prostate cancer, clinical evaluation of JANX014, and advancement of JANX011 for autoimmune diseases, while discontinuing JANX008. The company also announced a developmental candidate nomination under its collaboration with Bristol Myers Squibb, triggering a $35 million milestone payment, and maintains a strong cash position of $956.4 million.
Janux Therapeutics (Nasdaq:JANX) - Stock Analysis
Janux Therapeutics (JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and autoimmune diseases. The company's stock is currently trading at US$14.18, with analysts suggesting a fair value of US$44.13, indicating it is significantly undervalued. While Janux is not yet profitable, its revenue is forecast to grow by 53.48% per year, and it maintains a strong cash position with strategic partnerships.
Milestone payment and strong cash fuel Janux (NASDAQ: JANX) pipeline
Janux Therapeutics reported a net loss of $24.4 million for Q1 2026, consistent with the prior year, but maintained a robust cash position of $956.4 million. The company received a $35 million milestone payment from Bristol Myers Squibb and continues to advance its clinical pipeline, including JANX007, JANX014, and JANX011, while discontinuing JANX008 to reallocate resources.
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M
Janux Therapeutics, Inc. (JANX) reported its Q1 revenue at $3.7 million, falling short of the FactSet estimate of $4.4 million. The biopharmaceutical company, which specializes in tumor-activated immunotherapies for cancer, also recently announced the discontinuation of clinical development for its cancer drug candidate JANX008. This financial update follows several analyst downgrades and price target adjustments for Janux Therapeutics in April.
FMR LLC files 13G/A on JANX (NASDAQ: JANX) for 2.54M shares
FMR LLC has filed an Amendment No. 5 to Schedule 13G/A, reporting beneficial ownership of 2,535,723.63 shares of Janux Therapeutics Inc. (JANX), which represents 4.2% of the class. The filing indicates that FMR LLC has sole dispositive power over these shares, with an "as-of" date of March 31, 2026, and signatures executed on May 5, 2026. Abigail P. Johnson is also listed with the same sole dispositive power.
EX-99.1
Janux Therapeutics, Inc. announced a proposed underwritten public offering of $175.0 million of its common stock, with an option for underwriters to purchase an additional $26.25 million. The company, a clinical-stage biopharmaceutical firm, intends to use the net proceeds to advance the clinical development of its internal product pipeline and for general corporate purposes. BofA Securities, TD Cowen, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. are serving as joint book-running managers for the offering.
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing
Janux Therapeutics Inc. (NASDAQ: JANX) is exhibiting near-term weak sentiment, potentially signaling a resumption of long-term weakness after a neutral shift. The stock is currently testing support, with an exceptional 132.2:1 risk-reward setup targeting a 38.8% gain versus a 0.3% risk. AI models have generated distinct trading strategies including a Position Trading Strategy, Momentum Breakout Strategy, and Risk Hedging Strategy, along with multi-timeframe signal analysis.
Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Guggenheim analyst Bradley Canino has reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $68.00. This comes despite a recent downgrade from Barclays, while Bank of America Securities also issued a Buy rating for the company. Janux Therapeutics recently reported a quarterly revenue of $7.88 million and a GAAP net loss of $31.95 million for the quarter ending December 31.
Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors
Several insiders at Janux Therapeutics (NASDAQ:JANX) have sold shares over the past year, which could be a warning sign for investors. Although insider selling can have various explanations, significant sales from multiple insiders warrant further investigation. While the insiders still hold a fair chunk of the company, the sales and two existing warning signs suggest caution for potential investors.
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68
Guggenheim has reiterated its Buy rating on Janux Therapeutics (JANX.US) and maintained a target price of $68. This indicates the firm's continued confidence in the company's financial outlook and stock performance.
Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership
Point72 entities, including Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen, have reported a 5.0% beneficial ownership stake in Janux Therapeutics (JANX). This disclosure was made via a Schedule 13G filing, indicating they collectively hold 3,069,759 shares with shared voting and dispositive power as of April 28, 2026. The filing explicitly states no sole voting or dispositive power and highlights a Joint Filing Agreement among the reporting persons.
Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake
Point72 affiliates, including Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen, have reported a 5.0% beneficial ownership stake in Janux Therapeutics (JANX) as of April 28, 2026. This stake consists of 3,069,759 shares, held through Point72 Associates, an investment fund managed by Point72 Asset Management. The Schedule 13G filing indicates that the reporting persons do not directly own the shares but maintain shared voting and dispositive power.
Janux Therapeutics | ARS: Annual Report to Security Holders
This article from Janux Therapeutics consists solely of an annual report to security holders, indicated by the 'ARS' designation. The content provides a formal financial and operational status update for shareholders as legally required.
[ARS] Janux Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Janux Therapeutics, Inc. (JANX) on April 28, 2026. The filing is categorized with low impact and neutral sentiment. The article also provides a brief overview of Janux Therapeutics, including its market cap, industry, and recent news and SEC filings.
Janux Therapeutics Adjusts Board Class Structure for Director
Janux Therapeutics Inc. (JANX) has reclassified director Eric Dobmeier from Class III to Class II on its board to rebalance the director classes. This procedural move ensures the continuity of Dobmeier's service and responsibilities, maintaining balanced staggered terms for stable corporate governance. Despite this, TipRanks' AI Analyst Spark rates JANX as "Neutral" due to weak financial performance, though noting a strong balance sheet and a positive collaboration with BMS.
JonesTrading Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $28
JonesTrading has initiated coverage of Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a target price of $28 for the biotechnology company's stock. This new analyst coverage reflects a positive outlook on Janux Therapeutics' future performance.
Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat
Janux Therapeutics rebalanced its board by moving director Eric Dobmeier from a Class III to a Class II seat. This change, effective April 28, 2026, was made to achieve a more equal distribution of members among the three director classes. Dobmeier's service is considered continuous for all purposes, including equity awards and compensation, and he will remain on the Compensation Committee.
Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote
Janux Therapeutics (JANX) has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Stockholders will vote on the re-election of two Class II directors, the ratification of Ernst & Young LLP as its independent auditor, and an advisory vote on executive officer compensation. The proxy statement outlines executive compensation, which includes base salaries, performance-based cash incentives, and equity awards, with the board recommending approval of all proposals.
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move
Janux Therapeutics has decided to discontinue its early-stage cancer program, JANX008, following an internal review that determined the therapy did not meet the company's investment threshold. Despite some positive responses and insights gained into tumor biology and masking strategies, musculoskeletal toxicities limited its potential. The company plans to reallocate resources to other programs with stronger potential, emphasizing a disciplined approach to pipeline development.
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38
Stifel has reiterated its Buy rating on Janux Therapeutics (JANX.US) and maintained its target price at $38. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics has announced the discontinuation of clinical development for JANX008, an EGFR-targeted TRACTr program, following an internal review of Phase 1a data. Although some durable responses were observed, the overall efficacy did not meet the company's criteria to continue development compared to other pipeline programs. This decision allows Janux to prioritize resources on other promising immunotherapies, while insights gained from JANX008 will inform the broader TRACTr platform strategy.
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline
JANX stock saw an after-hours increase following the company's announcement to discontinue its cancer program. This decision was made to allow JANX to focus on its remaining pipeline. The move suggests a strategic shift in the company's research and development priorities.
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics has announced the discontinuation of clinical development for JANX008, its EGFR-targeted TRACTr program, after an internal review of Phase 1a data showed insufficient overall magnitude and consistency of activity despite some durable responses. The company will reallocate resources to other promising pipeline programs, but noted that insights gained from JANX008, such as its differentiated tolerability profile and ability to enable outpatient dosing, support the broader TRACTr platform's potential. This decision reflects Janux's disciplined approach to pipeline prioritization based on high standards for safety, activity, and differentiated profiles.
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline
Janux Therapeutics (JANX) announced the discontinuation of its experimental program JANX008 for solid tumor indications, causing its stock to edge up 1% after hours. The company decided to halt development after early-stage trials showed that while durable responses were observed, the overall efficacy and consistency were not sufficient compared to other pipeline programs. Janux aims to prioritize resources on more promising candidates, including experimental drugs for prostate cancer and autoimmune diseases.
Janux to Halt Development of Cancer Drug Candidate JANX008
Janux Therapeutics has announced its decision to halt the development of JANX008, one of its cancer drug candidates. This news comes amidst recent adjustments by analysts, with Barclays downgrading the company and revising its price target. Janux Therapeutics is a clinical-stage biopharmaceutical company focusing on tumor-activated immunotherapies for cancer.
Janux Therapeutics Ends JANX008 Clinical Development | JANX Stock News
Janux Therapeutics (NASDAQ: JANX) announced the discontinuation of further clinical development for its JANX008 program, an EGFR-targeted TRACTr, following a review of Phase 1a data. While some durable responses were observed, the overall magnitude and consistency of activity did not meet the company's predefined development criteria compared to other pipeline opportunities. This decision allows Janux to reallocate resources to programs with higher potential, reinforcing its disciplined portfolio prioritization strategy.
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57
This article reports a significant 11.93% decrease in the price target for Janux Therapeutics (JANX), bringing it down to $54.57. The contributing factors or the source of this re-evaluation are not detailed within the provided content.
Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Janux Therapeutics Inc. (JANX). As of the provided data, JANX is trading at $15.39, down $0.27 (-1.75%). The page also notes that there are currently no analyst ratings or earnings information available for the company.
Janux Therapeutics Inc (JANX) News, Articles, Events & Latest Updates
This article provides a compilation of recent news and updates regarding Janux Therapeutics Inc (JANX), including market data, analyst ratings, and company announcements. Key highlights include the initiation of a Phase 1 study for JANX014, a $35 million milestone payment from Bristol Myers Squibb, and a "Moderate Buy" average rating from brokerages.
